Taking Wegovy after gallbladder removal: what you need to consider

Why the gallbladder question matters for semaglutide users

The gallbladder's job is to store and release bile, helping the body break down fats. When it is removed, bile drips continuously from the liver into the small intestine rather than arriving in controlled bursts after a meal. Most people adapt to this over months; many live without symptoms. But the system is more sensitive to anything that alters digestion's pace.

Semaglutide works in part by slowing gastric emptying, food sits longer in the stomach before moving on. For someone without a gallbladder, that delay interacts with the continuous bile drip in ways that can cause looser stools, urgency, or cramping, particularly early in treatment when the body is still adjusting to the medicine. These effects are not guaranteed, and many people do not experience them at all. The point is simply that the gut's tolerance for change is lower when the gallbladder is absent, so symptoms that another person might find mild can feel more disruptive.

There is also a separate structural consideration. The known side-effect profile of Wegovy includes an elevated risk of gallbladder problems (gallstones, cholecystitis, and bile duct issues) documented in the STEP clinical trial programme and noted in the NHS patient information for semaglutide. Without a gallbladder, stones cannot form there. They can, however, form in the bile ducts themselves (choledocholithiasis), and this is a harder clinical problem. Your prescriber will want to know whether any stones were found in the ducts at the time of your surgery, and whether you have had any biliary symptoms since.

What rapid weight loss adds to the picture

Wegovy produces meaningful weight loss for many people, around 15% on average over 68 weeks in the STEP 1 trial, as reported in the New England Journal of Medicine. That is the whole point. But rapid weight loss, from any cause, increases the tendency of bile to become more concentrated and to form sludge or stones.

For people who still have their gallbladder, this is the mechanism behind Wegovy's known gallbladder risk. For people who have already had it removed, the gallbladder itself is gone, but the bile ducts are not. Concentrated bile that might previously have settled in the gallbladder can instead accumulate in the ducts. The risk is real, not theoretical, though it is not so high that cholecystectomy history alone disqualifies someone from treatment. What it does is raise the importance of monitoring, dose titration that is paced appropriately, and honest reporting of any symptoms.

If you want a fuller picture of the broader gallbladder risk associated with semaglutide, the relationship between Wegovy and gallbladder health is covered in more detail separately.

When to seek medical help, and what to watch for

This is the section to read carefully. Some digestive side effects from semaglutide are common, expected, and generally self-limiting: nausea and loose stools often settle within the first few weeks at a new dose. Others are signals that need prompt attention.

Seek urgent medical help if you develop severe, persistent pain in the upper right abdomen or centre of the abdomen, especially if it radiates to your back or right shoulder, or is accompanied by fever, vomiting, or yellowing of the skin or whites of the eyes. These can indicate bile duct obstruction or acute pancreatitis, both of which require prompt assessment. The MHRA's Drug Safety Update guidance on GLP-1 medicines makes clear that pancreatitis is a known, though infrequent, serious side effect, severe, persistent stomach pain that reaches through to the back is the key warning symptom.

Pale or clay-coloured stools and dark urine alongside any abdominal pain can suggest a biliary problem and should not be left until a routine appointment. If you are unsure whether what you are experiencing is a normal GI side effect or something more significant, contact your prescriber or call NHS 111, and it is worth familiarising yourself with the side effects associated with the Wegovy 1ml dose so you know what is expected at that stage of treatment. Suspected side effects can also be reported to the MHRA via the Yellow Card scheme, that reporting genuinely helps inform ongoing safety monitoring for everyone on these medicines.

How the consultation works if you have had your gallbladder removed

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician, reading your answers, the same day you submit them. Your surgical history is part of that review. The prescriber will look at when your cholecystectomy was, whether there were any complications, and how your digestion has been since. They may want to know whether you are currently taking any medicines for bile acid malabsorption or digestive symptoms.

If Wegovy is considered appropriate, your prescriber will discuss the slower titration schedule that tends to be sensible when GI sensitivity is higher, starting at 0.25mg and moving up gradually, with time to assess how each dose sits before increasing. That pacing is built into the licensed Wegovy schedule anyway; it may simply matter more for you.

A question our prescribers hear regularly is whether having no gallbladder is an automatic barrier to treatment. It is not. It is a factor (one among several) that a prescriber weighs against your overall health picture, your weight-related conditions, and what you stand to gain. If you would like that conversation, you can check your eligibility and start a free consultation. Further context on semaglutide after gallbladder removal and on taking semaglutide without a gallbladder is also available if you want to read more before deciding.